Analysis of factors associated with extremity ulceration in diabetic subjects with peripheral neuropathy;Análise de fatores associados à ulceração de extremidades em indivíduos diabéticos com neuropatia periférica

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 7, 2007, Pages 1134-1142

  Porciúncula, Mariana V P ^a   Rolim, Luiz Clemente P ^a   Garofolo, Luciana ^a   Ferreira, Sandra Roberta G ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Foot ulceration; Haluxbrachial index; Inflammatory markers; Peripheral arterial disease; Peripheral neuropathy

Indexed keywords

EID: 38149080667     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000700017     Document Type: Article

References (31)

1. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ 3rd, O'Brien PC. Risk factors for severity of diabetic polineuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999;22:1479-86.
2. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-86.
3. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies. Diabetes Care 2005;28:955-62.
4. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcer: predicting which ones will not heal. Am J Med 2003;115:627-31.
5. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG. A prospective study of risk factors for diabetic foot ulcer. Diabetes Care 1999;22:1036-42.
6. Adler A, Boyko E, Ahroni J, Smith D. Lower extremity amputation in diabetes: The independent effects of peripheral vascular disease, sensory neuropathy and foot ulcers. Diabetes Care 1999;22:1029-35.
7. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
8. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
9. Moss SE, Klein R, Klein B. The 14-year incidence of lowerextremity amputation in a diabetic population. Diabetes Care 1999;22:951-9.
10. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJM. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003;26:1435-8.
11. Armstrong DG, Lavery LA, Vela AS, Quebedeaux TL, Fleischli JG. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration. Arch Intern Med 1998;158:289-92.
12. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998;21:1071-5.
13. Gross JL, Nehme M. Detecção e tratamento das complicações crônicas do diabetes melito: Consenso da Sociedade Brasileira de Diabetes e Conselho Brasileiro de Oftalmologia. Rev Ass Brasil 1999;45:279-84.
14. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:463-654.
15. National Cholesterol Education Program Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. JAMA 2001;285:248-97.
16. III Consenso Brasileiro de Hipertensão Arterial. Arq Bras Endocrinol Metab 1999;43:257-86.
17. Perkins AB, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001;24:250-6.
18. Aso Y, Fujiwara Y, Inukai T, Takemura Y. Power spectral analysis of heart rate variation in diabetic patients with neuropathic foot ulceration. Diabetes Care 1998;21:1173-6.
19. Sosenko JM, Gadia MT, Fournier AM, O'Connell MT, Aguiar MC, Skyler JS. Body stature as a risk factor for diabetics' sensory neuropathy. Am J Med 1986;80:1031-4.
20. Ziegler D, Mayer P, Wiefels K, Gries FA. Evaluation of thermal, pain and vibration sensation thresholds in newly diagnosed type 1 diabetic patients. Neurosurg Psych 1998;11:1420-4.
21. Boulton AJM, Kubrusly DB, Bowker JH, Skyler JS, Sosenko JM. Impaired vibratory perception and diabetic foot ulceration. Diabet Med 1986;3:335-7.
22. Garrow AP, Boulton AJM. Vibration perception threshold - a valuable assessment of neuronal dysfunction in people with diabetes. Diabetes Metab Res Rev 2006;22:411-9.
23. rd, O'Brien PC. Risk factors for severity of diabetic polineuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999;22:1479-86.
24. Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1999;22:1479-86.
25. Skyler JS. Diabetic complication. The importance of glucose control. Endocrinol Metab Clin North Am 1996;25:243-54.
26. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
27. Beavan S, Winteran J. Nerve growth factor (NGF) differentially regulates the chemosensitivity of adult rat cultured sensory neurons. J Neurosci 1995;15:4918-26.
28. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin-10. J Exp Med 1991;174:1549-55.
29. Rose B, Shin DI, Friese G, Othamn T, Poschen U, Herder C, et al. Sustained elevated serum concentrations of the proinflammatory cytokine IL-6 in type 2 diabetes patients with diabetic foot syndrome. Diabetologia 2005;48:A356 (abstract).
30. Lobmann R, Motzkau M, Lehnert H, Ambrosch A. Cytokine analyses in wound fluids of the diabetic foot syndrome reflects inflammation and the various healing stages. Diabetologia 2005;48:A356 (abstract).
31. Orchard TJ, Strandness Jr DE. Assessment of peripheral vascular disease in diabetes. Report and recommendations of an International Workshop - American Heart Association and American Diabetes Association. Diabetes Care 1993;16:1199-209.